Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$35.5 million for Q1 2026.

  • Quarterly Net Cash Flow fell 138.96% to -$35.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Mar 2026, up 114.03% year-over-year, with the annual reading at $153.0 million for FY2025, 156.48% up from the prior year.
  • Net Cash Flow came in at -$35.5 million for Q1 2026, down from -$16.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $451.8 million in Q2 2023 to a low of -$195.7 million in Q4 2024.
  • The 5-year median for Net Cash Flow is $7.2 million (2024), against an average of $17.0 million.
  • Year-over-year, Net Cash Flow tumbled 3266.85% in 2022 and then soared 7962.69% in 2023.
  • MoonLake Immunotherapeutics' Net Cash Flow stood at -$1.7 million in 2022, then skyrocketed by 7962.69% to $132.9 million in 2023, then tumbled by 247.18% to -$195.7 million in 2024, then surged by 91.66% to -$16.3 million in 2025, then crashed by 117.93% to -$35.5 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Net Cash Flow are -$35.5 million (Q1 2026), -$16.3 million (Q4 2025), and $44.3 million (Q3 2025).